Medicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational Highlights
Updated cash guidance provides runway into at least the middle of calendar 2026
Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL-2 superkine by exceeding ORR benchmarks demonstrated with other competing therapies in similar checkpoint resistant tumor types
A patient with pancreatic cancer and a melanoma cancer patient remain cancer free for 18 and 6 months, respectively, after achieving complete resolution of their target and non-target lessions without any additional treatment following MDNA11 monotherapy
Company remains on track to complete enrollment in the Phase 1/2 ABILITY-1 monotherapy and combination arms and provide top-line clinical data readouts in calendar H2 2025
Partnering efforts for bizaxofusp, Medicenna's phase-3 ready recurrent glioblastoma program, and IND-enabling studies for its conditionally activated bi-specific anti-PD-1 x IL-2 superkine program continue to advance
Recently granted patents in major markets solidify portfolio IP position across the entire platform
TORONTO and HOUSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQX:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, today reported financial results and corporate highlights for the fiscal quarter ended June 30, 2025, as well as anticipated corporate milestones.
"We enter the second half of 2025 encouraged by positive clinical data from the Phase 1/2 ABILITY-1 trial, and remain on track to complete enrollment and report top-line data from both the monotherapy and combination arms before year-end," said Fahar Merchant, Ph.D., President and CEO of Medicenna. "We are motivated by previously reported data, from each of the three tumor-specific cohorts, to pursue expedited regulatory pathways for MDNA11 in order to address critical unmet needs in patients who do not respond to blockbuster immunotherapies. In parallel, we are making strong progress with MDNA113, our lead candidate from the proprietary BiSKIT platform. This bi-functional anti-PD1-IL2 Superkine is engineered with integrated targeting and stealth capabilities, enabling tumor-specific activation while minimizing peripheral effects. We look forward to sharing further clinical updates at conferences and scientific events later this year."
PROGRAM AND BUSINESS UPDATE:Highlights for the three months ended June 30, 2025, along with recent developments, include:
MDNA11: IL-2 Superkine Program
MDNA11 continues to deliver strong signals of durable efficacy, including complete, long-lasting responses in hard-to-treat cancers and 30–50% response rates in high-dose patients across multiple tumor types, supporting its best-in-class potential.
Clinical and strategic momentum is progressing well, with active enrollment in the Phase 1/2 ABILITY-1 trial and key data readouts are expected in H2 2025.
MDNA113: First-in-Class Anti-PD-1-IL-2 Bispecific Superkine
Promising preclinical data for MDNA113 was presented at AACR 2025, highlighting its tumor-targeted design and strong anti-tumor activity in IL-13Rα2–positive tumor models, supporting development potential in cancers affecting over 2 million patients annually.
MDNA113 is a first-in-class ...
